Here are the 424B prospectus supplements from COMPASS Pathways Plc (CMPS) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow CMPS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CMPS filings page.
COMPASS Pathways plc is offering 17,500,000 American Depositary Shares and pre-funded warrants to purchase 1,250,000 ADSs. The ADSs are being sold at $8.00 per ADS and the pre-funded warrants at $7.9999 each, with aggregate public offering proceeds shown as $149,999,875 and estimated net proceeds of approximately $140.5 million after underwriting discounts and estimated offering expenses.
The offering includes a 30-day underwriters' option to purchase up to 2,812,500 additional ADSs. The company intends to use net proceeds to fund its ongoing COMP005 and COMP006 Phase 3 trials for treatment-resistant depression, a Phase 2b/3 trial in PTSD, accelerate commercial readiness activities, and for working capital and general corporate purposes.
COMPASS Pathways is offering $150,000,000 of American Depositary Shares and pre-funded warrants in a primary equity raise, plus ADSs issuable on warrant exercise. Underwriters also have a 30-day option to buy up to an additional $22.5 million of ADSs. Net proceeds are earmarked mainly to fund COMP360 Phase 3 trials in treatment-resistant depression, a Phase 2b/3 PTSD trial, and commercial launch preparation, alongside general corporate uses.
The company recently reported that both pivotal Phase 3 trials, COMP005 and COMP006, met their primary endpoints, with 25 mg COMP360 showing highly statistically significant and clinically meaningful MADRS improvements versus control and a generally well-tolerated safety profile. Preliminary cash and cash equivalents were about $149.6 million as of December 31, 2025, and management warns that without this or similar financing there is substantial doubt about the ability to continue as a going concern.